CNSP
CNS Pharmaceuticals, Inc. [CNSP] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
CNSP Stock Summary
Top 10 Correlated Stocks
CNSP
In the News
CNSP Financial details
Company Rating
-
Market Cap
2.59M
Income
-18.86M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
3
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-0.25
Forward P/E
-
PEG
0.05
P/S
-
P/B
-2.76
P/C
-
P/FCF
-0.51
Quick Ratio
0.22
Current Ratio
0.51
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-5.66
EPS next Y
-
EPS next Q
-
EPS this Y
-55.44%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-12.04%
-
-
-
-
SMA20
-2.45%
SMA50
-5.14%
SMA100
-29.18%
Inst Own
-
Inst Trans
-
ROA
-816%
ROE
-616%
ROC
10.91%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.22-4.4
52W High
-
52W Low
-
RSI
35.2
Rel Volume
1.51
Avg Volume
443.89K
Volume
668.33K
Perf Week
-41.27%
Perf Month
-41.8%
Perf Quarter
-57.72%
Perf Half Y
-61.08%
-
-
-
-
Beta
1.088
-
-
Volatility
1.41%, 0.75%
Prev Close
-13.87%
Price
3.23
Change
-25.23%
Company Profile
- Volume Average 443.89K
- Market Capitalization 2.59M
- Employee 3
- CEO Mr. John Michael Climaco Esq., J.D.
- Headquarters Houston,TX,US
- IPO Date 2019-11-08
-
Website
https://www.cnspharma.com 
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.
